A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to
infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in
participants with rheumatoid arthritis (RA) not adequately responding to methotrexate (MTX).